TL;DR
This paper investigates aminoguanidine's potential to inhibit the oxidative modification of LDL, a key process in atherosclerosis. They found that aminoguanidine effectively prevents LDL from becoming a ligand for scavenger receptors on macrophages by trapping reactive aldehydes, suggesting a dual benefit in combating diabetes complications and atherosclerosis.
What Problem Does This Paper Address?
Atherosclerosis, a major cause of heart disease, is strongly linked to the oxidative modification of low-density lipoprotein (LDL). When LDL is oxidized, its apolipoprotein B (apo B) undergoes chemical changes, particularly the derivatization of lysine residues by reactive aldehydes. This modified LDL is no longer recognized by normal cellular LDL receptors but is instead avidly taken up by scavenger receptors on macrophages. This process contributes to the formation of foam cells, a hallmark of atherosclerotic plaques.
The paper draws an analogy to advanced glycosylation end products (AGEs) that form in chronic hyperglycemia (like in diabetes). AGEs also involve modifications of lysine residues and lead to protein crosslinking, contributing to diabetic complications. Aminoguanidine is known to inhibit AGE formation by binding to early glycosylation products. The researchers hypothesized that aminoguanidine might similarly inhibit LDL oxidation by binding to the reactive aldehydes produced during lipid peroxidation, thereby preventing their conjugation to apo B.
Methods
The researchers employed several key experimental techniques:
- LDL Oxidation: Unlabeled and radioiodinated LDL (¹²⁵I-LDL) were oxidized using two methods: incubation with cultured rabbit aortic endothelial cells (EC) or incubation with copper ions (Cu²⁺). These oxidations were performed in the presence or absence of varying concentrations of aminoguanidine.
- Lipid Peroxidation Measurement:
- TBARS Assay: Thiobarbituric acid-reactive substances (TBARS) were measured to quantify lipid peroxidation products, expressed as nmol equivalents of malondialdehyde (MDA).
- Conjugated Diene Formation: The absorbance at 234 nm was monitored over time to track the formation of conjugated dienes, an early indicator of lipid peroxidation.
- Protein Modification Assessment:
- Electrophoretic Mobility: Changes in the electrophoretic mobility of LDL on agarose gels were used to assess the negative charge increase on apo B due to modifications.
- Fluorescence Spectroscopy: Oxidized LDL exhibits characteristic fluorescence due to Schiff base adducts formed between reactive aldehydes and lysine residues. This fluorescence was measured to quantify protein modification.
- MDA-LDL Modification: LDL was deliberately modified with exogenous MDA in the presence or absence of aminoguanidine. The percentage of lysine residues modified by MDA was determined using the trinitrobenzenesulfonate assay.
- Macrophage Uptake and Degradation: ¹²⁵I-LDL, after oxidation, was incubated with mouse peritoneal macrophages. The rate of LDL degradation was measured by quantifying the trichloroacetic acid-soluble radioactivity in the medium and cell-associated radioactivity.
- Antioxidant Activity Assay: Aminoguanidine's potential to act as a direct antioxidant was tested using a xanthine/xanthine oxidase system to generate superoxide anions, monitoring the reduction of cytochrome c.
Datasets
Not discussed in the paper. The experiments utilized isolated LDL, cultured endothelial cells, and primary macrophages from mice.
Key Insights and Ideas
- Aminoguanidine as an Aldehyde Scavenger: The central idea is that aminoguanidine doesn't necessarily act as a traditional antioxidant by directly neutralizing free radicals. Instead, it preferentially binds to reactive aldehydes (like MDA) that are byproducts of lipid peroxidation. This "aldehyde trapping" prevents these reactive species from modifying apo B.
- Dual Benefit Hypothesis: The paper proposes that aminoguanidine could be beneficial in two ways: by inhibiting AGE formation (relevant to diabetes complications) and by inhibiting LDL oxidation (relevant to atherosclerosis). This dual action makes it a potentially powerful therapeutic agent.
- Selective Inhibition: Aminoguanidine appears to inhibit the modification of apo B that leads to scavenger receptor recognition, even if overall lipid peroxidation (measured by diene conjugation) proceeds to a similar plateau. This suggests it specifically targets the formation of the "ligand" for macrophages.
- Concentration-Dependent Effects: The study highlights dose-dependent effects of aminoguanidine, with significant inhibition of LDL modification and macrophage uptake observed at concentrations of 5-10 mM.
Key Results
- Aminoguanidine significantly inhibited the oxidative modification of LDL, as evidenced by reduced apo B lysine modification (measured by fluorescence) and decreased electrophoretic mobility.
- This inhibition of LDL modification led to a dose-dependent decrease in the subsequent uptake and degradation of oxidized LDL by macrophages. At 5 mM aminoguanidine, macrophage degradation was reduced by up to 60%.
- Aminoguanidine prevented MDA from derivatizing lysine residues on apo B.
- While aminoguanidine at higher concentrations (≥5 mM) prolonged the lag phase of conjugated diene formation, it did not significantly affect the final plateau level of lipid peroxidation, suggesting it primarily inhibits the rate of propagation rather than the overall extent.
- Aminoguanidine did not demonstrate direct antioxidant activity in a xanthine/xanthine oxidase assay.
Limitations and Future Work
- In Vitro vs. In Vivo: The study was conducted in vitro. While promising, the efficacy and safety of aminoguanidine in preventing atherosclerosis in vivo need to be confirmed.
- Tissue Penetration: Aminoguanidine is a relatively hydrophilic compound. The authors suggest that more hydrophobic derivatives might achieve better penetration into the hydrophobic core of LDL and be more effective at lower concentrations.
- Mechanism of Antioxidant Effect: While aminoguanidine didn't act as a direct radical scavenger in the tested system, its ability to delay conjugated diene formation suggests it might act as an antioxidant by inhibiting propagation, possibly by reacting with peroxy radicals. Further investigation into this mechanism is warranted.
- Clinical Relevance of Concentrations: The paper notes that plasma levels of about 13 mM have been reported in rodents after oral feeding, suggesting the tested concentrations might be achievable in vivo. However, clinical studies in humans are still underway.
- Future Directions: The authors propose that it would be important to determine if aminoguanidine can inhibit atherosclerosis in nondiabetic animal models and prevent diabetic complications and atherosclerosis in diabetic animals. They also suggest that separating the effects of AGE formation from LDL oxidation inhibition could be achieved by using LDL oxidized in the presence of aminoguanidine.
Summary updated